RT Journal Article
SR Electronic
T1 Aerosolized Hydrogen Peroxide Decontamination of N95 Respirators, with Fit-Testing and Virologic Confirmation of Suitability for Re-Use During the COVID-19 Pandemic
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.17.20068577
DO 10.1101/2020.04.17.20068577
A1 T. Hans Derr
A1 Melissa A. James
A1 Chad V. Kuny
A1 Devanshi Patel
A1 Prem P. Kandel
A1 Cassandra Field
A1 Matthew D. Beckman
A1 Kevin L. Hockett
A1 Mark A. Bates
A1 Troy C. Sutton
A1 Moriah Szpara
YR 2020
UL http://medrxiv.org/content/early/2020/12/24/2020.04.17.20068577.abstract
AB In response to the current demand for N95 respirators by healthcare workers responding to the COVID-19 pandemic, we evaluated decontamination of N95 respirators using a low concentration aerosolized hydrogen peroxide (aHP) system. This system dispenses a consistent atomized spray of micron-sized, low concentration, hydrogen peroxide (H2O2) particles over a treatment cycle. Multiple N95 respirator models were subjected to ten or more cycles of respirator decontamination, and masks were periodically assessed for qualitative and quantitative fit testing to verify respirator integrity. In parallel, we assessed the ability of aHP treatment to inactivate multiple viruses absorbed onto masks, including phi6 bacteriophage, HSV-1, CVB3, and SARS-CoV-2. Given that SARS-CoV-2 is transmitted via expired respiratory droplets and aerosols, it is critical to address respirator safety for reuse. This study provided experimental validation of a suitable aHP treatment process that decontaminates the respirators while maintaining N95 function. After ten rounds of aHP treatment, respirators passed N95 filtration efficiency testing. Virus inactivation by aHP was comparable to the sterilization of commercial spore-based biological indicators. These data demonstrate that the aHP process is effective, on the basis of zero failure rate on fit-testing of respirators, effective decontamination of multiple virus species including SARS-CoV-2, successful sterilization of bacterial spores, and filtration efficiency maintained at or greater than 95%. Collectively, these studies support the use of specific aHP decontamination protocol that permits safe reuse of N95 respirators by healthcare providers.Importance The ongoing COVID-19 pandemic has led to unprecedented pressure on healthcare and research facilities to provide adequate personal protective equipment. Given that the current pandemic is caused by a respiratory viral pathogen, the availability of highly protective respirator facepieces is critical to limit inhalation of this virus. While respirator facepieces were designed for single-use and disposal, the pandemic has increased overall demand for N95 respirators, and corresponding manufacturing and supply chain limitations have necessitated the safe reuse of respirators when necessary. The biosafety level 3 (BSL3) facility used in this study regularly utilizes aerosolized hydrogen peroxide (aHP) to decontaminate equipment and spaces. We repurposed this technology for N95 respirator decontamination during the COVID-19 pandemic. Results from virus inactivation, biological indicators, respirator fit testing, and filtration efficiency testing all indicated that the process was effective at rendering N95 respirator safe for reuse.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Pennsylvania State University. SARS-CoV-2 research in Dr. Troy Sutton's laboratory was initiated by a seed grant from The Huck Institutes of Life Sciences at Pennsylvania State University, and Dr. Sutton's research is further supported by the USDA National Institute of Food and Agriculture, Hatch project 4605.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is included in this publication. Supplemental Table 1 is available from the authors & included in the peer-review submission.aHPaerosolized hydrogen peroxide (H2O2)BSLbiosafety levelCOVID-19coronavirus disease 2019CVB3coxsackievirus B3H2O2hydrogen peroxideHPMhydrogen peroxide vapor monitorHSV-1herpes simplex virus 1phi6Pseudomonas phi6 bacteriophageOSHAOccupational Safety and Health AdministrationQLFTqualitative fit testQNFTquantitative fit-testSARS-CoV-2severe acute respiratory syndrome coronavirus 2VPHPVapor-phase hydrogen peroxide.